The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma

Elizabeth L. Thompson 1,2,*, Jiayi J. Hu 1,2 and Laura J. Niedernhofer 1,2

1 Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA; hu000250@umn.edu (J.J.H.; lniedern@umn.edu (L.J.N.)
2 Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN 55455, USA
* Correspondence: thom4573@umn.edu

Simple Summary: Advances in melanoma treatment include v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors that target the predominant oncogenic mutation found in malignant melanoma. Despite initial success of the BRAF inhibitor (BRAFi) therapies, resistance and secondary cancer often occur. Mechanisms of resistance and secondary cancer rely on upregulation of pro-survival pathways that circumvent senescence. The repeated identification of a cellular senescent phenotype throughout melanoma progression demonstrates the contribution of senescent cells in resistance and secondary cancer development. Incorporating senotherapeutics in melanoma treatment may offer a novel approach for potentially improving clinical outcome.

Abstract: BRAF is the most common gene mutated in malignant melanoma, and predominately it is a missense mutation of codon 600 in the kinase domain. This oncogenic BRAF missense mutation results in constitutive activation of the mitogen-activate protein kinase (MAPK) pro-survival pathway. Several BRAF inhibitors (BRAFi) have been developed to specifically inhibit BRAFV600 mutations that improve melanoma survival, but resistance and secondary cancer often occur. Causal mechanisms of BRAFi-induced secondary cancer and resistance have been identified through upregulation of MAPK and alternate pro-survival pathways. In addition, overriding of cellular senescence is observed throughout the progression of disease from benign nevi to malignant melanoma. In this review, we discuss melanoma BRAF mutations, the genetic mechanism of BRAFi resistance, and the evidence supporting the role of senescent cells in melanoma disease progression, drug resistance and secondary cancer. We further highlight the potential benefit of targeting senescent cells with senotherapeutics as adjuvant therapy in combating melanoma.

Keywords: melanoma; BRAF mutation; BRAF inhibitors; secondary cancer; resistance; senescence; senotherapeutics

1. Introduction

Melanoma is a cancer originating from melanocytes, the pigment producing cells in the skin [1]. In the United States alone, there will be an estimated 106,110 new cases and 7180 deaths from melanoma in 2021. Melanoma represents 5.6% of all new cancer cases in the US, and the rate of new cases has been increasing over the past 40 years. The risk of melanoma increases with age, but sex differences have been reported with women having a higher risk under age 50 and men having a higher risk over age 50 [2,3]. Other common risk factors for melanoma include ultraviolet (UV) light exposure, nevi (moles), fair skin, having prior melanoma or other skin cancer, family history of melanoma, or having a compromised immune system. Most nevi will never develop into melanoma; however, people with many nevi (greater than 50) or with congenital melanocytic nevi or dysplastic nevi are also at higher risk. In rare cases, increased risk of melanoma can be caused by an inherited DNA repair deficiency disorder called xeroderma pigmentosum [3,4].
Melanoma accounts for only 4% of all diagnosed skin cancers, but it is the most lethal type of skin cancer, resulting in 80% of skin cancer deaths [4]. The stage of melanoma diagnosis can determine both the survival rate and course of treatment [5]. Currently, the first treatment strategy for all stages of melanoma is surgical resection, which is highly curative for early stages of the disease. Melanoma is associated with a 5-year relative survival rate of 93.3%, but for distant metastatic disease the 5 year relative survival is only 29.8% [3]. If cancer cells have spread to the lymph nodes, then adjuvant or targeted therapy would be considered. New melanoma adjuvant treatments include immunotherapy with programmed cell death protein 1 (PD-1), programmed death ligand-1 (PD-L1), or cytotoxic T-lymphocyte associated protein 4 (CTLA4) inhibitors or targeted drug therapies with BRAF, MAPK/ERK kinase 1 (MEK), or stem cell factor receptor (c-KIT) inhibitors [6–8]. For advanced metastatic melanoma, other options include radiation and genotoxic chemotherapy [3], but they are typically less effective than the newer targeted treatments.

Despite melanoma having a high passenger mutation load due to ultraviolet (UV) mutagenesis, several cancer driving mutations have been identified. The three most prevalent genes mutated in melanoma are BRAF, neuroblastoma RAS viral oncogene homolog (NRAS), and neurofibromatosis 1 (NF1), and all participate in the mitogen-activated protein kinase (MAPK) signaling cascade that regulates cell proliferation [9–12]. In fact, constitutive activating mutations in BRAF are the most common oncogenic mutations, present in 40–60% of all melanoma cases [11,13,14]. Additionally, NRAS mutations are found in 15–30% of melanoma patients [13–15], and NF1 mutations are found in 12–18% of all melanomas [11,12]. Several other well-known cancer genes that have been implicated in melanoma including phosphatase and tensin homolog (PTEN), tumor protein p53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), and mitogen-activated protein kinase kinase 1 (MAP2K1) [11]. Familial melanoma studies identified the CDKN2A locus, which encodes for protein p16INK4a and p19ARF, and their loss of expression is common in melanoma [16,17]. Also, amplification of microphthalmia-associated transcription factor (MITF) occurs in 15% of melanomas, activating mutation of the receptor tyrosine kinase, c-KIT (~20–25% of melanomas), and germline melanocortin 1 receptor (MC1R) variants are lineage-specific casual alterations in melanoma [18–20]. Furthermore, novel driver mutations were identified in Rac family small GTPase 1 (RAC1), AT-rich interactive domain-containing protein 2 (ARID2), protein phosphatase 6 catalytic subunit (PPP6C), and serine/threonine-protein kinase 19 (STK19) through genome-wide studies of a large number of melanomas [11,21]. Knowledge of the patient-specific mutations help guide treatment options with new targeted therapies.

Senescence has long been known as a double-edged sword in cancer biology. It is essential for cancer prevention and therapy effectiveness, but can also pave the way for resistance [22–24]. Senescence is a permanent cell cycle arrest induced by a variety of cell stressors including aging, genotoxic stress, or tissue injury. These cellular stressors lead to permanent activation of the DNA damage response (DDR) through ataxia telangiectasia mutated (ATM). The activated DDR results in the stabilization of tumor suppressor protein 53 (p53) and its transcriptional targets cyclin-dependent kinase inhibitor 1 (p21\(^{\text{CIP1}}\)) and cyclin-dependent kinase inhibitor 2A (p16\(^{\text{INK4a}}\)), resulting in cell cycle arrest through inhibition of cyclin dependent kinases which prevent the phosphorylation of retinoblastoma (RB) and entrance into S phase of the cell cycle [25–28]. Senescent cells are characterized by increased cell size, senescent-associated beta-galactosidase (SA-β-gal) activity [29], upregulation of anti-apoptotic pathways [30,31], decreased lamin B1 [32], and a senescence-associated secretory phenotype (SASP) [33]. The SASP is initiated by nuclear factor kappa B (NF-kB) signaling and is composed of proinflammatory cytokines, matrix metalloproteinases (MMPs) and growth factors [33,34]. These markers of senescence are routinely used to identify senescent cells; however, individually, none can confirm senescence.

In this review, we summarize the current understanding of BRAF mutations in melanoma. We explore the specific BRAF\(^{V600E}\) mutation and discuss additional gene mutations often found in conjunction with BRAF mutations that lead to melanoma. We
discuss current treatment with BRAF inhibitors (BRAFi) with secondary cancer side effects and resistance development. Finally, we evaluate the role of senescence in melanoma progression and treatment and propose intentionally targeting senescent cells as a novel treatment strategy to prevent secondary cancer and drug resistance.

2. BRAF Oncogene, Common Mutation BRAFV600E

BRAF is a cytoplasmic serine-threonine kinase in the MAPK pathway. Not only is BRAF the most common gene mutated in melanoma, but mutations in the kinase domain occur in over 60% of malignant melanomas. The predominate BRAF mutation site is valine 600, and 80–90% of the time it is the missense mutation V600E [35]. However, other missense mutations at this site are also found in melanoma including V600K (10–20%), V600R (5%), V600D (<5%) [14]. The amino acid change from valine to glutamic acid is a phosphomimetic mutation and results in constitutive activation of BRAF and the MAPK pathway. This missense mutation is associated with younger age of onset of melanoma and more aggressive disease [14,36,37]. The BRAFV600E mutation is often found in benign and dysplastic nevi and these nevi typically remain in growth arrest for decades without advancing to malignancy [15,38]. These nevi express p16INK4a and have increased senescence-associated acidic beta-galactosidase (SA-β-gal) activity, characteristic of senescent cells in permanent growth arrest. This senescence phenotype found in BRAFV600E nevi is presumed to be caused by the oncogene-induced senescence (OIS) induced by a robust activation of the DNA damage response due to hyper-replication [39–41]. Therefore, due to OIS, the BRAFV600E mutation alone is not sufficient for malignancy and is often accompanied by additional driving mutation(s) [21,42,43]. Studies have found mutations in PTEN, a negative regulator of the phosphoinositide 3-kinase (PI3K) pathway, to have an occurrence as high as 40% with BRAF mutations [11]. Other common gene mutations implicated with BRAF mutations in melanoma include CDKN2A, tumor protein p53 (TP53) and telomerase reverse transcriptase (TERT) [11,44]. Melanoma has a high mutational burden compared to most other solid tumors and these mutations are primarily consistent with UV mutagenesis. The typical UV mutation signature is a cytidine to thymine transition occurring at dipyrimidine sites [11]. Interestingly, it is a thymine to adenine transversion mutation that results in the BRAFV600E mutation [45]. The BRAFV600E mutation site is directly adjacent to several dipyrimidines, and BRAF tandem mutations in melanoma are relatively common [46,47] (Figure 1). Thus, this cancer driving mutation could be caused by an error-prone polymerase producing a mutation near, but not at sites of UV-induced cyclobutene pyrimidine dimer DNA adducts [45–48]. The strong selective advantage of the mutation can then drive its common occurrence. Understanding that these BRAF mutations are likely driven by UV mutagenesis and often result in OIS is important for the prevention and treatment of melanoma.

Determining the presence of a BRAF mutation has become a standard of care for advanced melanoma and can help direct treatment with targeted therapies [7,14]. BRAF mutant melanoma is often more clinically aggressive and occurs in younger patients, therefore early identification is essential for optimal disease management [14]. Additionally, detection of BRAFV600E mutations in circulating tumor-derived DNA (ctDNA) in patient peripheral blood is correlated with tumor burden [49–51]. In some cases, increasing ctDNA BRAFV600E can be used as a biomarker of melanoma disease progression post therapy [49–51]. Furthermore, combining ctDNA BRAFV600E detection with other markers of disease progression such as lactate dehydrogenase (LDH) or matrix metalloproteinase-9 (MMP-9) can add prognostic value [49,50]. However, additional advancements in identifying early signs of disease progression are necessary for improved outcomes in BRAFV600E mutant melanoma.
Figure 1. Common BRAF codon 600 missense mutations found in melanocytic lesions. Wild type BRAF encoding valine at codon 600 with dipyrimidines highlighted in blue with *. Dipyrimidines are common sites of UV mutagenesis resulting in C-T transitions and are prevalent surrounding BRAF codon 600. The Single mutation BRAF<sup>V600E</sup> T-A transversion mutation is the most common mutation in melanoma and is not typical of UV mutagenesis. Tandem mutations are commonly found in BRAF at codon 600 and include BRAF<sup>V600E</sup>, BRAF<sup>V600R</sup>, BRAF<sup>V600K</sup>, and BRAF<sup>V600D</sup>. All the Tandem mutations except BRAF<sup>V600D</sup> contain one C-T transition at a dipyrimidine site within the tandem mutation. The surrounding dipyrimidine sites and common tandem mutations highlight the possibility of UV mutagenesis and error-prone polymerase incorporation of incorrect bases at BRAF codon 600. BRAF, v-Raf murine sarcoma viral oncogene homolog B.

The Braf<sup>V600E</sup> mutation was evaluated in mice and embryonic expression resulted in embryonic lethality. When the Braf<sup>V600E</sup> mutation was induced in melanocytes, highly pigmented lesions occurred within 3–4 weeks, however, these nevi were non-malignant with a senescent phenotype [52]. Similar to humans, the Braf oncogene induces melanocyte senescence in mice and can transform immortalized murine melanocytes [53,54]. Additionally, Braf<sup>V600E</sup> has been found with other driving mutations, such as Pten. Mice with Pten knockout alone do not develop melanoma, but when combined with Braf<sup>V600E</sup> (Braf<sup>V600E</sup>/Pten<sup>−/−</sup> mice) there is rapid emergence of malignant lesions [52].

3. BRAF Inhibitors, Resistance and Secondary Cancer

Several BRAF inhibitors (BRAFi) that specifically target the BRAF<sup>V600</sup> mutant protein have been developed through structure-based drug design and including vemurafenib, dabrafenib and encorafenib. These drugs improve progression free survival (PFS) in Phase 3 randomized clinical trials in patients with metastatic melanoma and BRAF<sup>V600</sup> mutations. When compared to the standard of care chemotherapy, dacarbazine, the overall survival (OS) with vemurafenib was significantly increased from 9.7 months to 13.6 months and PFS increased from 1.6 months to 6.9 months [55]. Similarly, dabrafenib compared to dacarbazine treatment increased PFS in unresectable stage III melanoma from 2.7 to 5.1 months [56]. When the BRAFi, encorafenib was compared to vemurafenib with stage III and IV melanoma patients, the patients on either BRAF inhibitor had comparable PFS [57]. While initially very effective, melanoma resistance quickly develops to BRAFis, limiting their effectiveness.

Genetic alterations providing resistance to BRAFi are found in the majority of resistant tumors (Figure 2) [58–64]. The most common genetic changes for resistance result in
reactivation of the MAPK pathway. These occur through BRAF amplification, BRAF splice variants, or additional mutations in BRAF, RAS or MEK [58,59,62]. Loss of CDKN2A was also commonly found in BRAFi resistant melanomas and is linked to the MAPK pathway as an inhibitor of the downstream effectors cyclin D and cyclin-dependent kinase 4 (CDK4) [59,64]. The phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway was implicated as the second major pathway upregulated in BRAFi resistance. Several mutations in this pathway including loss of PTEN or upregulation of AKT or receptor tyrosine kinases (RTKs) are commonly found in resistant melanoma [43,52,58,62,65–67]. Overall, most BRAFi resistant melanomas have reactivated the MAPK pathway or upregulated the PI3K/AKT/mTOR pathway through specific mutations. However, altered epigenetic regulation and evasion of the immune system also occur to promote tumor proliferation and survival.

Several non-genetic mechanisms also contribute to melanoma progression and resistance including phenotypic switching, tumor microenvironment, inflammation, and epigenetic changes (Figure 3A). Rambow et al. investigated phenotypic switching associated with minimal residual disease (MRD) and drug resistance in melanoma [68]. The authors used patient-derived xenographs from BRAFV600E mutated tumors and subsequently treated the mice with BRAFi/MEKi. They found 60% of resistant cells had mutations in MAPK or PI3K/AKT pathways that helped drive drug resistance. However, these mutations were not observed at the MRD phase, indicating drug tolerance is also

**Figure 2.** BRAF inhibition and genetic mechanisms of secondary cancer and resistance. **BRAF Inhibition:** BRAFV600E results in constitutive activation of the pro-survival MAPK pathway. BRAF inhibitors target the oncogenic BRAF mutation and initially are highly effective. **Secondary Cancer:** BRAF inhibitors can paradoxically activate the MAPK pathway in cells with wild type BRAF and oncogenic RAS mutations by signaling through CRAF, resulting in cSCC development. The occurrence of cSCC is reduced when MEK inhibitors are used to further restrict the activation of the MAPK pathway. **Resistance** to both BRAF inhibition and MEK inhibition predominately develop through RAS, BRAFV600E, MEK, RTK, PTEN, or AKT mutations indicated by red stars. These mutations either reactivate the MAPK pathway or upregulate the PI3K/AKT/mTOR pro-survival pathway. cSCC, cutaneous squamous cell carcinoma; RTK, receptor tyrosine kinase; MAPK, mitogen activated protein kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B; ERK, extracellular signal-regulated kinase; MEK, MAPK/ERK Kinase 1; RAS, rat sarcoma; AKT, protein kinase B; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog.
Microphthalmia-associated transcription factor (MITF) has also been used in melanoma as an indicator of melanoma cell phenotype switching. The emergence of a drug resistant and invasive phenotype is associated with low expression of MITF, and in general, MITF is downregulated as disease progresses [68,70,71]. However, some heterogeneity in MITF expression is observed in MRD [68]. Decreased expression of MITF is also associated with senescence and increased genomic instability and the emergence of aggressive metastatic cells [72,73]. Proinflammatory cytokines released after treatment such as transforming growth factor beta (TGFβ), platelet-derived growth factor (PDGF), tumor necrosis factor alpha (TNFα), interleukin-1b (IL-1β), and interleukin-6 (IL-6) that can activate myofibroblast and contribute to chronic inflammation, fibrosis, and a pro-tumor microenvironment [71,74]. Hepatocyte growth factor secretion by cancer associated fibroblast (CAFs) can also active receptor tyrosine kinases (RTKs) and the MAPK and PI3K/AKT pathways driving drug resistance [75]. All of these cytokines associated with creating the proinflammatory and pro-tumor environment are also SASP factors that could be secreted by senescent cells in the tumor microenvironment [76–78].

High mobility group box protein 1 (HMGB1) has also been implicated in melanoma progression with higher expression correlating with poor survival [79]. However, excretion of HMGB1 is also associated with a proinflammatory and anti-tumor response through activation of dendritic cells and induction of T-cell activation after BRAFi and MEKi treatment [80]. HMGB1 is a damage-associated molecular pattern (DAMP) that is also secreted by senescent fibroblasts induced by several different types of cellular stress including OIS, protease inhibitor, and ionizing radiation (IR) [77].
Immune escape is a common occurrence for patients treated with BRAFi. Immune escape and metastatic disease are associated with increased CEACAM1, an intercellular adhesion protein that has immune modulation functions [81–83]. Furthermore, CEACAM1 expression is required for senescence maintenance [84] and detection of high levels of CEACAM1 in melanoma is associated with oxidative stress, immune dysfunction and metastatic disease [81–83,85]. BRAFi treatment initially downregulates CEACAM1, but its expression is restored with the development of drug resistance [85], indicating a contribution of senescent cells to drug resistance.

Finally, epigenetic factors contribute to melanoma progression and drug resistance. One example is enhancer of zeste homologue 2 (EZH2), which is a histone methyltransferase that can trimethylate lysine 27 in histone 3 (H3K21me3) and repress transcription. In melanoma, EZH2 expression is associated with poor prognosis [86]. Additionally, depletion of EZH2 can activate p21CIP1 and result in senescence [87]. Furthermore, alterations in expression of histone deacetylases (HDACs) and histone acetyltransferases can result in epigenetic changes leading to BRAFi resistance. Some resistant melanomas were found to downregulate HDACs (Sirtuin 2 and Sirtuin 6) and histone acetyltransferase (HAT1), or to upregulate HDAC8 [58]. Similarly, components of the SASP are altered with HDAC inhibition to senescent fibroblasts, promoting tumor growth [88]. Collectively, these studies establish parallels between the non-genetic mechanisms of resistance in melanoma and some of the pro-tumor characteristics of senescence cells (Figure 3A,B).

One of the most concerning side effects of BRAFi is non-melanoma skin lesions, including cutaneous squamous cell carcinoma (cSCC), which occur in 15–20% of patients. Although cSCC is another form of skin cancer, it arises from keratinocytes instead of melanocytes. Importantly, BRAFi treatment of cells with wild type BRAF leads unexpectedly to activation of the MAPK pathway, and this upregulation is fundamental for cSCC development [89–91]. This paradoxical activation of the MAPK pathway with BRAFi is often found in keratinocytes with existing RAS mutations. In fact, RAS mutations are found in up to 60% of BRAFi therapy-induced secondary cSCC [61,91,92]. Oncogenic RAS with BRAFi has been found to activate the MAPK pathway by signal through CRAF, an analog of BRAF [61,90,91]. While the BRAFi have very low target inhibition of wild type BRAF, this activation of CRAF can result in increased proliferation and tumorigenesis in RAS mutant cells (Figure 2) [90,93]. Additionally, there have been reports of melanoma patients treated with BRAFi that have developed non-cutaneous RAS driven cancers including leukemia and colon cancer [94–96]. Another potential driving mechanism for secondary cSCC is human papilloma virus (HPV) infection [97,98]. Multiple variations of beta-HPV have been found in cSCC that were induced by BRAFi treatment [99]. The concern over paradoxical activation of the MAPK pathway, secondary cancer development and resistance with BRAFi led to combination therapy testing.

4. Addressing Secondary Cancer and Resistance to BRAF Inhibitors

The use of MEK inhibitors (MEKi) in combination with BRAFi was to prevent the paradoxical and reactivation of the MAPK pathway that leads to resistance and cSCC development [58,93,100,101]. The addition of MEKi were successful in reducing the incidence of cSCC and increasing PFS, but resistance routinely still develops. The combination treatments are Vemurafenib with Cobimetinib [102], Dabrafenib with Trametinib [103], and Encorafenib with Binimetinib [57]. While the MEK inhibitors reduce secondary cSCC, the two drugs target the same molecular pathway, increasing the chances of resistance and secondary cancer to occur through alternative pathways (Figure 2).

5. Senescence in Tumorigenesis and Melanoma

Senescence is typically seen as a repressor of tumorigenesis by halting growth in premalignant cells [104]. However, when senescence cells are not cleared by immunosurveillance, a pro-inflammatory environment can emerge that drives aging pathologies, including cancer [22,104]. For example, while transient senescence is associated with efficient wound
healing, persistent senescent cells are associated with chronic wounds [105,106]. With increased age, there is an increase in senescent cells and an increase risk of cancer. The correlation of cancer with senescent cell burden was demonstrated using a genetic mouse model for inducible elimination of $p16^{INK4a}$-positive senescent cells. The continuous elimination of senescent cells in adult mice delayed the onset of age-associated cancer [107]. Furthermore, there is even evidence indicating the necessity of overriding senescence as a requirement for malignancy and increased cancer aggressiveness [60,108–111].

There are several characteristics of senescent cells that can contribute to tumorigenesis (Figure 3B). First, senescent cells are in a state of chronic DNA damage response (DDR) with an increase in DNA damage foci [112,113]. This chronic DDR leads to mitochondrial dysfunction and increased reactive oxygen species (ROS) that create a feedback loop to help maintain the DDR [114,115]. Persistent DNA damage and ROS production can precipitate intracellular changes that promote malignant transformation. Second, the senescence-associated secretory phenotype (SASP) is a mixture of cytokines, chemokines, growth factors, and proteases secreted from senescent cells and is credited with creating a pro-inflammatory and pro-tumor microenvironment [33]. The SASP has both paracrine and autocrine effects in maintaining senescence and spreading senescence to neighboring cells. Additionally, the SASP can induce both epithelial to mesenchymal transition (EMT) and reprogramming of cancer cells to a more stem-like phenotype [33,116,117]. Immunosenesce refers to age-related dysfunction of the immune system caused at least in part by immune cell senescence and low-grade chronic inflammation due to SASP (inflammaging). The SASP of the tumor microenvironment can drive both inflammaging and immunosenesce, resulting in reduced clearance and accumulation of senescent cells and tumor escape from immunosurveillance [74,118–122]. This impairment of the immune system also results in compromised immune surveillance that is vital for tumor progression and metastasis.

There is evidence of senescence or a senescence-like phenotype throughout the progression of BRAF mutant melanoma. A senescence phenotype is observed in pre-neoplastic cells where benign nevi express characteristic senescence markers with increased SA-β-gal activity, increased expression of $p16^{INK4a}$, decreased lamin B1, and these markers decrease as the tumor progresses [39,123,124]. Additionally, $BRAF^{V600E}$ melanoma cells have increased senescence characteristics with increased SA-β-gal activity and expression of SASP factors, including IL-8 and TGFβ, compared to wild type $BRAF$ melanoma cells. Moreover, therapy induced senescence (TIS) has been observed in vitro with Vemurafenib treatment resulting in increased SA-β-gal activity in both sensitive and resistance $BRAF^{V600E}$ mutant melanoma cells [60]. Of further interest, the secondary cSCC from BRAFi-treated melanoma patients stains strongly for $p16^{INK4a}$ [125,126]. Additionally, a senescent phenotype is often observed in HPV infected cells, HPV positive tumors, and from RAS oncogene expression [97–99,124,127], which are commonly found in BRAFi-induced secondary cSCC. Furthermore, BRAFi treatment initially increases the antitumor immunogenicity of melanoma, but when resistance develops the tumors revert to a low immunogenic state. This lower immunogenic state of the BRAF-resistant cells has fewer tumor infiltrating T-cells and NK cells and they are less effective at recognizing and killing the cancer cells [58,128], which are all characteristics of immunosenesce. Taken together, these studies demonstrate the potential role of senescence within melanocytes and the skin microenvironment that are influencing melanoma progression and secondary cancer occurrence.

6. Future Therapy Directions

While targeted therapies like BRAFi are highly effective therapeutics at first, melanoma resistance routinely develops. Cross-talk between pro-survival pathways is well-established and upregulation of alternate pathways, primarily PI3K/AKT/mTOR pathway, is consistently seen in resistance to BRAFi [129]. In addition, branched evolution of resistance with multiple pathways of acquired resistance have been found within the same melanoma
Furthermore, BRAFi resistant BRAF<sup>V600E</sup> melanoma cells can even become dependent on the BRAF inhibitor for proliferation [60]. All these examples highlight the necessity for adjuvant treatments that can target several anti-apoptotic pathways to prevent drug resistance, such as senotherapeutics.

Senotherapeutics are a class of drugs that targets senescent cells and include senolytics and senomorphics. Senolytics selectively kill senescent cells and senomorphics suppress the SASP without inducing apoptosis. However, the distinction between these two drug classifications can sometimes be cell-type specific with the same drug capable of having senolytic function on one cell type and senomorphic on another [130]. Senolytics have been shown to combat aging and improve healthspan by reducing frailty and attenuating common age-associated morbidities [130–133]. Now senolytics are being considered and used in combination therapy for cancers [119,134–136]. Senotherapeutics could aid in the elimination of senescent cells after therapy-induced senescence (TIS) to reduce the emergence of drug resistance and cancer recurrence [134,135]. Several senotherapeutics have the added benefit of targeting multiple anti-apoptotic pathways that are employed by senescent cells to stay alive [131]. In addition, several senotherapeutics are flavonoids found in many fruits and vegetables and, therefore, expected to have lower toxicity than chemotherapy drugs that target proliferating cells. In theory, senotherapy could aid the immune system in clearing BRAFi-induced senescent cancer cells, reducing the possibility of acquiring additional adaptations for resistance and secondary cancers.

Several senotherapeutics have been tested with melanoma cells in vitro with encouraging results and some clinical trials with melanoma patients have been conducted (Table 1). One senolytic being researched with melanoma is dasatinib, a broad-specificity receptor tyrosine kinase (RTK) inhibitor. EGFR is a RTK that is commonly upregulated as a mechanism of resistance to BRAFi [66] therefore, dasatinib has both senolytic activity [133] and targets RTKs in BRAFi resistance. Importantly, dasatinib inhibits the proliferation and invasion of even BRAFi-resistant melanoma cells [67]. Another senolytic, fisetin is a flavonoid found to extend the health and lifespan of both progeroid and aged wild-type mice [132]. Fisetin has been tested in melanoma cells in an in vitro 3-D model system and found to promote tumor regression [137]. Fisetin has inhibitory effects on the PI3K/AKT/mTOR pathway and demonstrated efficiency at inhibiting multiple cancers and specifically melanoma [138,139]. Quercetin is another flavonoid and senolytic that has been found to work synergistically with dasatinib to combat age-associated frailty and extend healthspan in pre-clinical models [130]. Quercetin inhibits the growth, invasiveness, and metastatic potential of melanoma cell lines [140]. Additionally, quercetin can be metabolized by tyrosinase, which is expressed in melanocytes, into additional anti-cancer compounds, potentially increasing its potency specifically for melanoma [141,142]. Finally, piperlongumine, a natural extract from the Piper Longum pepper plant induces apoptosis of melanoma cells [143]. The benefits of the highlighted senolytic drugs in melanoma treatment is two-fold. First, senolytics could aid clearance of senescent tumor cells to prevent resistant cells from emerging. Second, they target senescent cell anti-apoptotic pathways that are involved in secondary cancer and development of drug resistance [131]. Intermittent dosing of BRAFi has demonstrated improved efficacy against some therapy resistant melanoma [144], and these resistant tumors could potential benefit from alternating BRAFi treatment with a senotherapy recently termed the “one-two punch” [145]. This “one-two punch” treatment strategy suggests treating with a tumor targeted therapy to induce senescence and following with a senolytic to help clear the senescent cells [145]. Some of the long-term effects of chemotherapy treatment on cancer survivors include increased incident of age-associated diseases linked to senescence such as cardiovascular disease, neurodegeneration, and secondary cancer. Thus, the use of senotherapeutics as part of cancer management could improve cancer treatment effectiveness and the healthspan of cancer survivors.
Table 1. Clinical trials and other studies on applying senotherapeutics to melanoma. HSP: heat shock protein; Bcl-2/Bcl-xL: B-cell lymphoma 2/B-cell lymphoma extra-large; HDAC: histone deacetylase; OXR1: oxidation resistance 1; BET: bromodomain and extraterminal domain; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; mTOR: mammalian target of rapamycin; MIC: melanoma initiating cells This table is not an all-inclusive list of studies with senotherapeutics for melanoma, and a more extensive list of senotherapeutics used in additional cancers can be found in Prasanna, et al. [145].

| Drug | Mechanisms of Action | Treatment | Developmental Stage |
|------|----------------------|-----------|---------------------|
| Alvespimycin | HSP inhibitor | Alvespimycin hydrochloride | **Clinical Trail:** Phase 1; NCT00089362; Metastatic or unresectable solid tumors including melanoma  <br> Phase 1; NCT00248521; Adult solid tumor including melanoma [146] <br> **Discovery Phase:** human melanoma cell line [147] |
| Tanespimycin | HSP inhibitor | Tanespimycin | **Clinical Trail:** Phase 2; NCT00087386; Recurrent or phase III, IV melanoma  <br> Phase 1; NCT00004065; Refractory advanced solid tumors including melanoma or hematologic cancer  <br> Phase 2; NCT00104897; Metastatic malignant melanoma [148]  <br> Phase 2; Metastatic Melanoma [149] |
| Digoxin | Na+/K+ ATPase inhibitor | Trametinib and Digoxin | **Clinical Trail:** Phase 1; NCT02138292; Unresectable or metastatic BRAF wild-type melanoma [151]  <br> Phase 1; NCT01765569; Advanced BRAFV600E mutant melanoma |
| Navitoclax (ABT-263) | Bcl-2/Bcl-xL inhibitor | Dabrafenib, trametinib, and navitoclax  <br> Novitoclax and selumetinib | **Clinical Trail:** Phase 1/2; NCT01989585; BRAF mutant melanoma or unresectable or metastatic solid tumors  <br> **Discovery Phase:** Melanoma cell lines [152] |
| Dasatinib | Pan receptor tyrosine kinase inhibitor | Dasatinib  <br> Dendritic cell Vaccines + Dasatinib  <br> Dasatinib and Dacarbazine  <br> Dasatinib  <br> Dasatinib and Dacarbazine  <br> Dasatinib | **Clinical Trail:** Phase 2; NCT00700882; Melanoma (Skin) [153]  <br> Phase 2; NCT01876212; Metastatic melanoma  <br> Phase 1/2; NCT00597038; Metastatic Melanoma  <br> Phase 2; NCT00456605; Unresectable stage III melanoma or stage IV melanoma  <br> Phase 1; Advanced melanoma [154]  <br> Phase 1; Metastatic melanoma [155]  <br> **Discovery Phase:** Melanoma cell lines [67] |
Table 1. Cont.

| Drug                        | Mechanisms of Action                              | Treatment       | Developmental Stage |
|-----------------------------|---------------------------------------------------|-----------------|--------------------|
| Panobinostat (LBH589)       | Pan HDAC inhibitor                                | Panobinostat    | Clinical Trail:    |
|                             |                                                   | Panobinostat    | Phase 1; NCT01065467; Metastatic |
|                             |                                                   | and             | Melanoma           |
|                             |                                                   | Ipilimumab      | Phase 1; NCT02032810; Unresectable |
|                             |                                                   | Temozolomide,  | stage III/IV melanoma |
|                             |                                                   | Decitabine,     | Phase 1/2; NCT00925132; Metastatic |
|                             |                                                   | Panobinostat    | Melanoma [156]     |
|                             |                                                   | (LBH589)        | Phase 1; metastatic melanoma [157] |
| Curcumin analog, EF24      | Promote degradation of anti-apoptotic Bcl-2 proteins | EF24            | Discovery Phase:   |
|                             |                                                   |                 | Malignant melanoma cell lines [158] |
| Piperlongumine             | Targets OXR1                                      | Piperlongumine  | Discovery Phase:   |
|                             |                                                   |                 | Human melanoma cell [143] |
| Ouabain                    | Na+/K+ ATPase inhibitor                           | Ouabain         | Discovery Phase:   |
|                             |                                                   |                 | Malignant melanoma cell lines [159,160] |
| ABT-737                    | Bcl-2/Bcl-xL inhibitor                            | ABT-737 and PLX4720 | Discovery Phase: Human melanoma cell lines and primary melanoma cell culture [161] |
|                             |                                                   | ABT-737 and GSI | Non-MIC (bulk of melanoma) and MICs [162] |
|                             |                                                   | (γ-Secretase Inhibitor) | |
| JQ1                        | BET inhibitor                                     | JQ1 and vemurafenib | Discovery Phase: BRAF mutant vemurafenib-resistant melanoma cells [163] |
| Quercetin                  | Activates estrogen receptors and inhibits PI3 kinase | Quercetin       | Discovery Phase:   |
|                             |                                                   |                 | Melanoma cell lines [140–142,164,165] |
| Fisetin                    | Blocks PI3K/AKT/mTOR pathway                      | Fisetin         | Discovery Phase:   |
|                             |                                                   |                 | Melanoma cell lines [137,138,166–168] |

7. Conclusions

Early-stage melanoma is curable, but once metastases have occurred, the chance of survival diminishes significantly. Several targeted therapies have been developed toward oncogenic BRAF in malignant melanoma that significantly improve PFS, but resistance often develops. Throughout the progression of disease and treatment of BRAF<sup>V600E</sup> driven melanoma, senescence induction and escape are recurring themes from cancer initiation to secondary skin cancers (cSCC), and drug resistance (Figure 4). The cancer cells must escape OIS induced by the BRAF<sup>V600E</sup> mutation in stable nevi to become malignant. The BRAFi therapy-induced senescence (TIS) in the cancer cells, and the development of secondary cSCCs with BRAF inhibitor treatment relies on upregulation of the MAPK pathway or alternative pathways in keratinocytes that often have senescence driving alterations such as RAS oncogene activation or HPV infection. Finally, the emergence of resistance occurs through upregulation of anti-apoptotic pathways like the MAPK pathway and AKT/PI3K/mTOR to override senescence induction. This repeated failure of senescence maintenance to control disease progression represents an opportunity for combining the use of senotherapeutics in melanoma treatment regimens for BRAF<sup>V600E</sup> mutated cancer. Particularly considering the evidence of cancer cells that escape from senescence can be primed as more stem-like, aggressive, and drug resistant. Several senotherapeutics have been tested on melanoma cells and show promising results, but further in-vivo studies are necessary to confirm these results and advance senotherapeutics for melanoma treatment.
Figure 4. The role of senescent cells in cancer progression and resistance. Pre-neoplastic lesions with BRAF\textsuperscript{V600E} or RAS mutations can acquire senescent cells through oncogenic induced senescence (OSI). The OSI cells can spread senescence to nearby cells through their senescent associated secretory phenotype (SASP). If these senescent cells are not cleared by the immune system, the SASP can produce a pro-inflammatory and pro-tumor microenvironment with increased DNA damage, oxidative stress, and immunosenescence resulting in malignant transformation. Therapy induced senescence (TIS) by BRAFi is initially beneficial in combating malignant melanoma, but can lead to increased senescence, drug resistance, and aggressive, stem-like tumor phenotype. Senotherapeutics can reverse all phases of disease progression by targeting pro-survival pathways, reducing SASPs and/or by aiding the immune system in clearing senescent cells.

Author Contributions: The review was conceived by E.L.T. and L.J.N. and the first draft was written by E.L.T. and J.J.H., which was subsequently edited by L.J.N. All authors have read and agreed to the published version of the manuscript.

Funding: E.L.T. was funded by the Children’s Cancer Research Fund Emerging Scientist Award and by NIA Postdoctoral Training Grant T32 AG029796. L.J.N. was funded by U01 ES029603.

Conflicts of Interest: L.J.N. is a co-founder of NRTK Biosciences, a start-up biotechnology company developing senolytic drugs.

References
1. Shain, A.H.; Bastian, B.C. From melanocytes to melanomas. Nat. Rev. Cancer 2016, 16, 345–358. [CrossRef] [PubMed]
2. American Cancer Society. Cancer Facts & Figures 2020. Available online: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html (accessed on 16 April 2021).
3. National Cancer Institute. Melanoma of the Skin—Cancer Stat Facts. Available online: https://seer.cancer.gov/statfacts/html/melan.html (accessed on 16 April 2021).
4. Miller, A.J.; Mihm, M.C. Melanoma. N. Engl. J. Med. 2006, 355, 51–65. [CrossRef] [PubMed]
5. Berwick, M.; Erdei, E.; Hay, J. Melanoma Epidemiology and Public Health. Dermatol. Clin. 2009, 27, 205–214. [CrossRef] [PubMed]
6. Leonardi, G.C.; Candido, S.; Falzone, L.; Spandidos, D.A.; Libra, M. Cutaneous melanoma and the immunotherapy revolution (Review). Int. J. Oncol. 2020, 57, 609–618. [CrossRef] [PubMed]
7. Patel, H.; Yacoub, N.; Mishra, R.; White, A.; Yuan, L.; Alanazi, S.; Garrett, J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 2020, 12, 482. [CrossRef] [PubMed]
8. Falzone, L.; Salomone, S.; Libra, M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front. Pharmacol. 2018, 9, 1300. [CrossRef]
9. Mehnert, J.M.; Kluger, H.M. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Curr. Oncol. Rep. 2012, 14, 449–457. [CrossRef]
10. Luo, Y.; Zhang, Z.; Liu, J.; Li, L.; Xu, X.; Yao, X.; Dai, Z.; Wang, X.; Yang, S.; Wu, H.; et al. Characterizations of Gene Alterations in Melanoma Patients from Chinese Population. *BioMed Res. Int.* **2020**, *2020*, 6096814. [CrossRef]

11. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arolt, S.T.; Iemielinski, M.; Theurillat, J.-P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al. A Landscape of Driver Mutations in Melanoma. *Cell* **2012**, *150*, 251–263. [CrossRef]

12. Kiuru, M.; Busam, K.J. The NF1 gene in tumor syndromes and melanoma. *Lab. Investig.* **2017**, *97*, 146–157. [CrossRef]

13. Burd, C.E.; Liu, W.; Huynh, M.V.; Waqas, M.A.; Gillahan, J.E.; Clark, K.S.; Fu, K.; Martin, B.L.; Jeck, W.R.; Souroullas, G.P.; et al. Mutation-Specific RAF Oncogenicity Explains NRAS Codon 61 Selection in Melanoma. *Cancer Discov.* **2014**, *4*, 1418–1429. [CrossRef]

14. Cheng, L.; Lopez-Beltran, A.; Massari, F.; MacLennan, G.T.; Montironi, R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. *Mod. Pathol.* **2018**, *31*, 24–38. [CrossRef] [PubMed]

15. Liu, Y.; Sheikh, M.S. Melanoma: Molecular Pathogenesis and Therapeutic Management. *mol. Cell. Pharmacol.* **2014**, *6*, 228.

16. Chin, L. The genetics of malignant melanoma: Lessons from mouse and man. *Nat. Rev. Cancer* **2003**, *3*, 559–570. [CrossRef]

17. Yang, G.; Rajadurai, A.; Tsao, H. Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma. *Cancer Discov.* **2014**, *4*, 1418–1429. [CrossRef]

18. Flaherty, K.T.; Hodi, F.S.; Fisher, D.E. From genes to drugs: Targeted strategies for melanoma. *Nat. Rev. Cancer* **2012**, *12*, 349–361. [CrossRef]

19. Garraway, L.A.; Widlund, H.R.; Rubin, M.A.; Getz, G.; Berger, A.J.; Ramaswamy, S.; Beroukhim, R.; Milner, D.A.; Grantor, S.R.; Du, J.; et al. Integrative genomic analyses identify MITF as a lineage survival oncogene in malignant melanoma. *Nature* **2005**, *436*, 117–122. [CrossRef]

20. Carvaljo, R.; Antonescu, C.; Wolchok, J.; Chapman, P.; Roman, R.; Teitcher, J.; Panagos, K.; Busam, K.; Chmielowski, B.; Lutzky, J.; et al. KIT as a Therapeutic Target in Metastatic Melanoma. *JAMA* **2011**, *305*, 2327–2334. [CrossRef] [PubMed]

21. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.; Goh, G.; Choi, M.; et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat. Genet.* **2012**, *44*, 1006–1014. [CrossRef]

22. Campisi, J. Aging, Cellular Senescence, and Cancer. *Annu. Rev. Physiol.* **2013**, *75*, 685–705. [CrossRef]

23. Lee, S.; Lee, A.J.-S. Cellular senescence: A promising strategy for cancer therapy. *BMN* **2019**, *52*, 35–41. [CrossRef]

24. Wyld, L.; Bellantuono, I.; Tchkonia, T.; Morgan, J.; Turner, O.; Foss, F.; George, J.; Danson, S.; Kirkland, J.L. Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies. *Cancers* **2020**, *12*, 2134. [CrossRef] [PubMed]

25. Alcorta, D.A.; Xiong, Y.; Phelps, D.; Hannon, G.; Beach, D.; Barrett, J.C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 13742–13747. [CrossRef] [PubMed]

26. Hugdahl, E.; Kalvenes, M.B.; Puntervoll, H.E.; Ladstein, R.G.; AAkslen, L. BRAF-V600E expression in primary nodular melanoma. *Cell. Signal.* **2007**, *19*, 1020–1028. [CrossRef] [PubMed]

27. Takahashi, A.; Ohtani, N.; Yamakoshi, K.; Iida, S.-I.; Tahara, H.; Nakayama, K.; Nakayama, K.I.; Ide, T.; Saya, H.; Hara, E. Mitogenic signalling and the p16INK4a–Rb pathway cooperate to enforce irreversible cellular senescence. *Nature* **2006**, *44*, 1291–1297. [CrossRef]

28. Yousefzadeh, M.; Henpita, F.; Sun, Y.; Muñoz, D.P.; Goldstein, J.N.; Nelson, P.S.; Desprez, P.Y.; Campisi, J. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. *PLoS Biol.* **2008**, *6*, e301. [CrossRef] [PubMed]

29. Carvajal, R.; Antonescu, C.; Wolchok, J.; Chapman, P.; Roman, R.; Teitcher, J.; Panagos, K.; Busam, K.; Chmielowski, B.; Lutzky, J.; et al. KIT as a Therapeutic Target in Metastatic Melanoma. *JAMA* **2011**, *305*, 2327–2334. [CrossRef] [PubMed]

30. Ryu, S.J.; Oh, Y.S.; Park, S.C. Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts. *Cell Death Differ.* **2007**, *14*, 1020–1028. [CrossRef] [PubMed]

31. Chen, W.; Kang, J.; Xia, J.; Li, Y.; Yang, B.; Chen, B.; Sun, W.; Song, X.; Xiang, W.; Wang, X.; et al. p53-related apoptosis resistance and tumor suppression activity in UVB-induced premature senescent human skin fibroblasts. *Int. J. Mol. Med.* **2008**, *21*, 645–653. [CrossRef]

32. Kefford, R.F. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. *J. Clin. Oncol.* **2005**, *23*, 117–122. [CrossRef] [PubMed]

33. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Mitochondrial dysfunction during senescence. *Nat. Rev. Mol. Cell Biol.* **2006**, *7*, 75–84. [CrossRef] [PubMed]

34. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). *Cell. Signal.* **2012**, *24*, 835–845. [CrossRef]

35. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woolfenden, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. *Nature* **2004**, *423*, 947–951. [CrossRef] [PubMed]

36. Hugdahl, E.; Kalvenes, M.B.; Puntervoll, H.E.; Ladstein, R.G.; A.Akslen, L. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. *Br. J. Cancer* **2011**, *114*, 801–808. [CrossRef] [PubMed]

37. Du, J.; et al. Integrative genomic analyses identify MITF as a lineage survival oncogene in malignant melanoma. *Nature* **2005**, *436*, 117–122. [CrossRef] [PubMed]

38. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). *Cell. Signal.* **2012**, *24*, 835–845. [CrossRef]

39. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woolfenden, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. *Nature* **2004**, *423*, 947–951. [CrossRef] [PubMed]

40. Hugdahl, E.; Kalvenes, M.B.; Puntervoll, H.E.; Ladstein, R.G.; A.Akslen, L. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. *Br. J. Cancer* **2011**, *114*, 801–808. [CrossRef] [PubMed]
38. Pollock, P.M.; Harper, U.L.; Hansen, K.S.; Yudt, L.M.; Stark, M.S.; Robbins, C.M.; Moses, T.Y.; Hostetter, G.; Wagner, U.; Kakareka, J.W.; et al. High frequency of BRAF mutations in nevi. Nat. Genet. 2003, 33, 19–20. [CrossRef]
39. Michaloglou, C.; Vredeveld, L.C.W.; Soengas, M.S.; Denoyelle, C.; Kuilman, T.; Van Der Horst, C.M.A.M.; Majoor, D.M.; Shay, J.W.; Mooi, W.J.; Peepers, D.S. BRAFV600-associated senescence-like cell cycle arrest of human nevi. Nature 2005, 436, 720–724. [CrossRef]
40. Bennett, D.C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003, 22, 3063–3069. [CrossRef]
41. Di Micco, R.; Fumagalli, M.; Cicalèse, A.; Piccinin, S.; Gasparini, P.; Luise, C.; Schurra, C.; Garre’, M.; Nuñiforo, P.G.; Bensimon, A.; et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444, 638–642. [CrossRef] [PubMed]
42. Vredeveld, L.C.; Possik, P.A.; Smit, M.A.; Meissl, K.; Michaloglou, C.; Horlings, H.M.; Ajauou, A.; Kortman, P.C.; Dankort, D.; McMahon, M.; et al. Abrogation of BRAFV600-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012, 26, 1055–1069. [CrossRef]
43. Nogueira, C.; Kim, K.-H.; Sung, H.; Paraíso, K.H.T.; Dannenberg, J.-H.; Bosenberg, M.; Chin, L.; Kim, M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010, 29, 6222–6232. [CrossRef]
44. Zhang, T.; Dutton-Regester, K.; Brown, K.M.; Hayward, N.K. The genomic landscape of cutaneous melanoma. Pigment. Cell Melanoma Res. 2016, 29, 266–283. [CrossRef] [PubMed]
45. Brash, D.E. UV Signature Mutations. Photochem. Photobiol. 2015, 91, 15–26. [CrossRef] [PubMed]
46. Thomas, N.E.; Alexander, A.; Edmiston, S.N.; Parrish, E.; Millikan, R.C.; Berwick, M.; Groben, P.; Ollila, D.W.; Mattingly, D.; Ashida, A.; Sakaizawa, K.; Mikoshiba, A.; Uhara, H.; Okuyama, R. Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in Chinese patients with melanoma. Oncol. Lett. 2018, 9, 856. [CrossRef]
47. Thomas, N.E.; Berwick, M.; Conway, K. Tandem BRAF Mutations in Primary Invasive Melanomas. J. Investig. Dermatol. 2004, 122, 1245–1250. [CrossRef] [PubMed]
48. Thomas, N.E.; Berwick, M.; Cordeiro-Stone, M. Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation? J. Investig. Dermatol. 2006, 126, 1693–1696. [CrossRef] [PubMed]
49. Rastogi, R.P.; Richa; Kumar, A.; Tyagi, M.B.; Sinha, R.P. Molecular Mechanisms of Ultraviolet Radiation-Induced DNA Damage and Repair. J. Nucleic Acids 2010, 2010, 592980. [CrossRef]
50. Tang, H.; Kong, Y.; Si, L.; Cui, C.; Sheng, X.; Chi, Z.; Dai, J.; Yu, S.; Ma, M.; Wu, X.; et al. Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. Oncol. Lett. 2017, 15, 1839–1844. [CrossRef]
51. Salemi, R.; Falzone, L.; Madonna, G.; Polesel, J.; Cirin, D.; Maillard, D.; Ascieto, P.A.; Libra, M.; Candido, S. MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Front. Pharmacol. 2018, 9, 856. [CrossRef]
52. Dankort, D.; Curley, D.P.; Cartledge, R.A.; Nelson, B.; Karnezis, A.N.; Jr, W.E.D.; You, M.J.; Depinho, R.A.; McMahon, M.; et al. Abrogation of BRAFV600-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2004, 18, 2334–2342. [CrossRef]
53. Dummer, R.; Ascierto, P.A.; Liszkay, G.; Garbe, C.; Schadendorf, D.; Krajsova, I.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.M.; Miller, W.H.; Kaempgen, E.; et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018, 380, 358–365. [CrossRef]
54. McArthur, G.A.; Chapman, P.B.; Robert, C.; Larkin, J.; Haanen, J.B.; Dummer, R.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P.A.; et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15, 323–332. [CrossRef]
55. Hauschild, A.; Grob, J.-J.; Demidov, L.V.; Joury, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.M.; Miller, W.H.; Kaempgen, E.; et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): A randomised, open-label, phase 3 trial. Lancet Oncol. 2018, 19, 603–615. [CrossRef]
56. Proietti, I.; Skroza, N.; Bernardini, N.; Tolino, E.; Balduzzi, V.; Marchesielli, A.; Michelini, S.; Volpe, S.; Mambrin, A.; Mangino, G.; et al. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers 2020, 12, 2801. [CrossRef]
57. Shi, H.; Cao, H.; Kong, X.; Hong, A.; Koya, R.C.; Moriceau, G.; Chodon, T.; Guo, R.; Johnson, D.B.; Dahlman, K.B.; et al. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discov. 2014, 4, 80–93. [CrossRef]
58. Krayem, M.; Najem, A.; Journe, F.; Morandini, R.; Sales, F.; Awada, A.; Ghanem, G.E. Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget 2018, 9, 31888–31903. [CrossRef]
59. Clynick, B.; Tabone, T.; Fuller, K.; Erber, W.; Meehan, K.; Millward, M.; Wood, B.A.; Harvey, N.T.; Fuller, K. Mutation Analysis of BRAF Inhibitor–Associated Squamousproliferative Lesions. J. Mol. Diagn. 2015, 17, 644–651. [CrossRef] [PubMed]
60. Sullivan, R.J.; Flaherty, K.T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 2013, 49, 1297–1304. [CrossRef]
61. Devji, T.; Levine, O.; Neupane, B.; Beyene, J.; Xie, F. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. JAMA Oncol. 2017, 3, 366–373. [CrossRef]
64. Nathanson, K.L.; Martin, A.-M.; Wubbenhorst, B.; Greshock, J.; Letrerero, R.; D’Andrea, K.; O’Day, S.; Infante, J.R.; Falchuck, G.S.; Arkenau, H.-T.; et al. Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). *Clin. Cancer Res.*, 2015, 19, 4868–4878. [CrossRef] [PubMed]

65. Paraizo, K.H.; Xiang, Y.; Rebecca, V.W.; Abel, E.V.; Chen, Y.A.; Munko, A.C.; Wood, E.; Fedorenko, I.V.; Sondak, V.K.; Anderson, A.R.; et al. PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BM Expression. *Cancer Res.*, 2011, 71, 2750–2760. [CrossRef]

66. Gross, A.; Nemetz-Rahn, A.; Nonnenmacher, A.; Tucholski, J.; Keilholz, U.; Fusi, A. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. *Target. Oncol.*, 2014, 10, 77–84. [CrossRef]

67. Girotti, M.R.; Pedersen, M.; Sanchez-Laorden, B.; Viros, A.; Turalic, S.; Niculescu-DuvaZ, D.; Zambon, A.; Sinclair, J.; Hayes, A.; Gore, M.; et al. Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. *Cancer Discov.*, 2013, 3, 158–167. [CrossRef]

68. Rambow, F.; Rogiers, A.; Marin-Bejar, O.; Aibar, S.; Femel, J.; Dewaele, M.; Karras, P.; Brown, D.; Chang, Y.H.; Debiec-Rychter, M.; et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. *Cell*, 2018, 174, 843–855.e19. [CrossRef] [PubMed]

69. Martin, N.; Ma, X.; Bernard, D. Regulation of cellular senescence by retinoid X receptors and their partners. *Mech. Ageing Dev.*, 2019, 183, 111131. [CrossRef]

70. Hoek, K.S.; Goding, C.R. Cancer stem cells versus phenotype-switching in melanoma. *Pigment. Cell Melanoma Res.*, 2010, 23, 746–759. [CrossRef]

71. Diazzi, S.; Tartare-Deckert, S.; Deckert, M. Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies. *Cancers*, 2020, 12, 1364. [CrossRef] [PubMed]

72. Giuliano, S.; Cheli, Y.; Ohanna, M.; Bonet, C.; Beuret, L.; Bille, K.; Loubat, A.; Hofman, V.; Hofman, P.; PonziGo, G.; et al. Microphltumia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas. *Cancer Res.*, 2010, 70, 3813–3822. [CrossRef]

73. Strub, T.; Giuliano, S.; Ye, T.; Bonet, C.; Keime, K.; Kobi, D.; Le Gras, S.; Cormont, M.; Ballotti, R.; Bertolotto, C.; et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. *Oncogene*, 2011, 30, 2319–2332. [CrossRef]

74. Fane, M.; Weeraratna, A.T. How the ageing microenvironment influences tumour progression. *Nat. Rev. Cancer*, 2020, 20, 89–106. [CrossRef] [PubMed]

75. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature*, 2012, 487, 500–504. [CrossRef] [PubMed]

76. Tominaga, K.; Suzuki, H.I. TGF-β Signaling in Cellular Senescence and Aging-Related Pathology. *Int. J. Mol. Sci.*, 2019, 20, 5002. [CrossRef] [PubMed]

77. Basisty, N.; Kale, A.; Jeon, O.H.; Kuehnemann, C.; Payne, T.; Rao, C.; Holtz, A.; Shah, S.; Sharma, V.; Ferrucci, L.; et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. *PLoS Biol.*, 2020, 18, e3000599. [CrossRef]

78. Schafer, M.J.; Zhang, X.; Kumar, A.; Atkinson, E.J.; Zhu, Y.; Jachim, S.; Mazula, D.L.; Brown, A.K.; Berning, M.; Aversa, Z.; et al. The senescence-associated secretome as an indicator of age and medical risk. *JCI Insight*, 2020, 5, 5. [CrossRef]

79. Li, Q.; Li, J.; Wen, T.; Zeng, W.; Peng, C.; Yan, S.; Tan, J.; Yang, K.; Liu, S.; Guo, A.; et al. Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. *Oncotarget*, 2014, 5, 6387–6403. [CrossRef]

80. Erkes, D.A.; Cai, W.; Sanchez, I.M.; Purwin, T.J.; Rogers, C.; Field, C.O.; Berger, A.C.; Hartsooh, E.J.; Rodeck, U.; Alnemri, E.S.; et al. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. *Cancer Discov.*, 2020, 10, 254–269. [CrossRef]

81. Thies, A.; Moll, I.; Berger, J.; Wagener, C.; Brümmer, J.; Schulze, H.-J.; Brunner, G.; Schumacher, U. CEACAM1 Expression in Cutaneous Malignant Melanoma Predicts the Development of Metastastic Disease. *J. Clin. Oncol.*, 2002, 20, 2530–2536. [CrossRef]

82. Wicklein, D.; Otto, B.; Suling, A.; Elies, E.; Lüers, G.; Lange, T.; Feldhaus, S.; Maar, H.; Schröder-Schwarz, J.; Brunner, G.; et al. CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells. *Sci. Rep.*, 2018, 8, 11893. [CrossRef]

83. Helfrich, I.; Singer, B.B. Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. *Cancers*, 2019, 11, 356. [CrossRef]

84. Sappino, A.-P.; Buser, R.; Seguin, Q.; Fernet, M.; Lesne, L.; Gumyopause, F.; Reith, W.; Favaudon, V.; Mandriota, S.J. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. *Oncogenesis*, 2012, 1, e7. [CrossRef]

85. Kifir-Eliachman, K.; Ortenberg, R.; Vizel, B.; Besser, M.J.; Barshack, I.; Schachter, J.; Nemlich, Y.; Markel, G. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. *Neoplasia*, 2018, 20, 401–409. [CrossRef]

86. Bachmann, I.M.; Halvorsen, O.J.; Collett, K.; Stefansson, I.M.; Straume, O.; Haukaas, S.A.; Salvesen, H.B.; Otte, A.P.; Akslen, L.A. EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast. *J. Clin. Oncol.*, 2006, 24, 268–273. [CrossRef]
87. Fan, T.; Jiang, S.; Chung, N.; Alikhan, A.; Ni, C.; Lee, C.-C.R.; Hornyak, T.J. EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression. Mol. Cancer Res. 2011, 9, 418–429. [CrossRef]

88. Pazzoli, E.; Alspach, E.; Milezarek, A.; Prior, J.; Piwnica-Worms, D.; Stewart, S.A. Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression. Cancer Res. 2012, 72, 2251–2261. [CrossRef]

89. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.C.; Stokoe, D.; Gloo, S.L.; Vigers, G.; et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, 431–435. [CrossRef]

90. Poulikakos, P.I.; Zhang, C.; Bollag, G.; Shokat, K.M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464, 427–430. [CrossRef]

91. Heidorn, S.J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010, 140, 209–221. [CrossRef] [PubMed]

92. Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J.S.; Kong, X.; Koya, R.C.; Flaherty, K.T.; et al. RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. N. Engl. J. Med. 2012, 366, 207–215. [CrossRef] [PubMed]

93. Domä, E.; Rupp, C.; Varga, A.; Kern, F.; Riegler, B.; Baccarini, M. Skin Tumorigenesis Stimulated by Raf Inhibitors Relies Upon Raf Functions That Are Dependent and Independent of ERK. Cancer Res. 2013, 73, 6926–6937. [CrossRef]

94. Abdel-Wahab, O.; Klimek, V.M.; Gaskell, A.A.; Viale, A.; Cheng, D.; Kim, E.; Rampal, R.; Bluth, M.; Harding, J.J.; Callahan, M.K.; et al. Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discov. 2014, 4, 538–545. [CrossRef]

95. Callahan, M.K.; Rampal, R.; Harding, J.J.; Klimek, V.M.; Chung, Y.R.; Merghoub, T.; Wolchok, J.D.; Solit, D.B.; Rosen, N.; Abdel-Wahab, O.; et al. Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. N. Engl. J. Med. 2012, 367, 2136–2121. [CrossRef] [PubMed]

96. Andrews, M.C.; Behren, A.; Chionh, F.; Madiadason, J.; Vella, L.J.; Do, H.; Dobrovic, A.; Tebbutt, N.; Cebon, J. BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition. J. Clin. Oncol. 2013, 31, e448–e451. [CrossRef] [PubMed]

97. Wu, J.; Cohen, D.; Rady, P.; Tyring, S. BRAF inhibitor-associated cutaneous squamous cell carcinoma: New mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br. J. Dermatol. 2017, 177, 914–923. [CrossRef] [PubMed]

98. Purdie, K.J.; Proby, C.M.; Rizvi, H.; Griffin, H.; Doorbar, J.; Sommerlad, M.; Feltkamp, M.C.; Van Der Meijden, E.; Inman, G.J.; et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF-Inhibition Therapy. Clin. Cancer Res. 2015, 21, 2624–2634. [CrossRef]

99. Pero, R.M.; Delmore, J.E.; Pandolfi, P.P. Senescence-associated reprogramming promotes cancer stemness. Nature 2018, 553, 96–100. [CrossRef]
136. Niedernhofer, L.J.; Robbins, P.D. Senotherapeutics for healthy ageing. Nat. Rev. Drug Discov. 2018, 17, 377. [CrossRef]

137. Pal, H.C.; Sharma, S.; Strickland, L.R.; Katiyar, S.K.; Ballestas, M.E.; Athar, M.; Elmets, C.A.; Afaq, F. Fisetin Inhibits Human Melanoma Cell Invasion through Promotion of Mesenchymal to Epithelial Transition and by Targeting MAPK and NFκB Signaling Pathways. PLoS ONE 2014, 9, e86338. [CrossRef]

138. Syed, D.; Adhami, V.; Khan, M.; Mukhtar, H. Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin. Anti-Cancer Agents Med. Chem. 2013, 13, 995–1001. [CrossRef]

139. Chamcheu, J.C.; Esnault, S.; Adhami, V.M.; Noll, A.L.; Baranger, M.; Mebiumi, S.; Roy, T.; Singh, S.S.; Huang, S.; Kousoulas, K.G.; Mukhtar, H. Fisetin, a 3',7',3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. Cells 2019, 8, 1089. [CrossRef] [PubMed]

140. Caltagirone, S.; Rossi, C.; Poggi, A.; Ranelli, F.O.; Natali, P.G.; Brunetti, M.; Aiello, F.B.; Piantelli, M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 2000, 87, 595–600. [CrossRef]

141. Harris, Z.; Donovan, M.G.; Branco, G.M.; Limesand, K.H.; Burd, R. Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Therapeutic Development Strategy. Front. Nutr. 2016, 3. [CrossRef]

142. Thangasamy, T.; Sittadjody, S.; Lanza-Jacoby, S.; Wachsberger, P.R.; Limesand, K.H.; Burd, R. Quercetin Selectively Inhibits Bioreduction and Enhances Apoptosis in Melanoma Cells That Overexpress Tyrosinase. Nutr. Cancer 2007, 59, 258–268. [CrossRef]

143. Song, X.; Gao, T.; Lei, Q.; Zhang, L.; Yao, Y.; Xiong, J. Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption. Nutr. Cancer 2018, 70, 502–511. [CrossRef] [PubMed]

144. Das Thakur, M.; Salangsang, F.; Landman, A.S.; Sellers, W.R.; Pryer, N.K.; Levesque, M.P.; Dummer, R.; McMahon, M.; Stuart, D.D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494, 251–255. [CrossRef]

145. Prasanna, P.G.; Citrin, D.E.; Hildesheim, J.; Ahmed, M.M.; Venkatachalam, S.; Riscuta, G.; Xi, D.; Zheng, G.; van Deursen, J.; Gotlib, H.S.; et al. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy. J. Natl. Cancer Inst. 2021, 113, 1676–1692. [CrossRef] [PubMed]

146. Pacey, S.; Wilson, R.H.; Walton, M.; Eatock, M.M.; Hardcastle, A.; Zetterlund, A.; Arkenau, H.-T.; Moreno-Farre, J.; Banerji, U.; Gore, M.; Chao, D.; Banerji, U.; Larkin, J.; Sarker, S.; Owen, K.; Asad, Y.; Raynaud, F.; Walton, M.; et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investig. New Drugs 2010, 30, 341–349. [CrossRef]

147. Shin, M.K.; Jeong, K.-H.; Choi, H.; Ahn, H.-J.; Lee, M.-H. Heat shock protein 90 inhibitor enhances apoptosis by inhibiting the BIM-dependent tumour cell death and inhibit acquired resistance. J. Dermatol. Sci. 2020, 90, 357–360. [CrossRef] [PubMed]

148. Pacey, S.; Gore, M.; Chao, D.; Banerji, U.; Larkin, J.; Sarker, S.; Owen, K.; Asad, Y.; Raynaud, F.; Walton, M.; et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investig. New Drugs 2010, 30, 341–349. [CrossRef]

149. Solit, D.B.; Osman, I.; Polsky, D.; Panagase, K.S.; Daud, A.; Goydos, J.S.; Teitcher, J.; Wolchok, J.D.; Germino, F.J.; Krown, S.E.; et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A Cancer Chemother. Pharmacol. 2011, 77, 117–202. [CrossRef]

150. Frankel, A.E.; Esko, N.; Goodfellow, R.; Eskiocak, U.; Gill, J.G.; Yuan, S.; Froehlich, T.W.; Ahn, C.; Morrison, S.J.; Eskiocak, U.; Gill, J.G.; Yuan, S.; Froehlich, T.W.; Ahn, C.; Morrison, S.J. Digoxin Plus Trametinib Resists Vemurafenib Resistance in Melanoma. Clin. Cancer Res. 2018, 24, 357–360. [CrossRef] [PubMed]

151. Shroff, R.M.; Hannon, S.J.; Buckhinder, I.; Grant, S.R.; Rodig, S.J.; Guerrini, F.; Becerra, C.; Tsai, S.; Chou, E.; Fisher, D.E.; Hodi, F.S. Phase I trial of panobinostat (LBH 589) in patients with metastatic melanoma. Cancer Med. 2016, 5, 3041–3050. [CrossRef]

152. He, Y.; Junling, Z.; Zhang, J.; Yang, Y.; Qian, Y.-W.; Zhou, D. The curcumin analog EF24 is highly active against chemotherapypotent melanoma cells. Curr. Cancer Drug Targets 2021, 21, 1. [CrossRef] [PubMed]

153. Da Silva, J.M.C.; Campos, M.L.A.; Teixeira, M.P.; Faustino, R.D.S.; Aleixo, R.C.; Cavalcante, F.J.P.; Gomes, L.R.O.; De Albuquerque, L.Z.; Azvedo, A.D.N.; Cabral, V.R.; et al. Ouabain pre-treatment modulates B and T lymphocytes and improves survival of melanoma-bearing animals. Int. Immunopharmacol. 2020, 86, 106772. [CrossRef] [PubMed]
160. Wang, L.; Cai, W.; Han, B.; Zhang, J.; Yu, B.; Chen, M. Ouabain Exhibited Strong Anticancer Effects in Melanoma Cells via Induction of Apoptosis, G2/M Phase Arrest, and Migration Inhibition. *OncoTargets Ther.* 2021, 14, 1261–1273. [CrossRef]

161. Wroblewski, D.; Mijatov, B.; Mohana-Kumaran, N.; Lai, F.; Gallagher, S.J.; Haass, N.K.; Zhang, X.D.; Hersey, P. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. *Carcinogenesis* 2012, 34, 237–247. [CrossRef]

162. Mukherjee, N.; Almeida, A.; Partyka, K.A.; Lu, Y.; Schwan, J.V.; Lambert, K.; Rogers, M.; Robinson, W.A.; Robinson, S.E.; Applegate, A.J.; et al. Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments. *Oncotarget* 2016, 7, 84594–84607. [CrossRef]

163. Zhao, B.; Cheng, X.; Zhou, X. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma. *Melanoma Res.* 2018, 28, 521–526. [CrossRef] [PubMed]

164. Kim, S.-H.; Yoo, E.-S.; Woo, J.-S.; Han, S.-H.; Lee, J.-H.; Jung, S.-H.; Kim, H.-J.; Jung, J.-Y. Antitumor and apoptotic effects of quercetin on human melanoma cells involving JNK/P38 MAPK signaling activation. *Eur. J. Pharmacol.* 2019, 860, 172568. [CrossRef]

165. Soll, F.; Ternent, C.; Berry, I.M.; Kumari, D.; Moore, T.C. Quercetin Inhibits Proliferation and Induces Apoptosis of B16 Melanoma Cells In Vitro. *ASSAY Drug Dev. Technol.* 2020, 18, 261–268. [CrossRef]

166. Wang, K.; Hu, D.-N.; Lin, H.-W.; Yang, W.-E.; Hsieh, Y.-H.; Chien, H.-W.; Yang, S.-F. Fisetin induces apoptosis through mitochondrial apoptosis pathway in human uveal melanoma cells. *Environ. Toxicol.* 2018, 33, 527–534. [CrossRef] [PubMed]

167. Sechi, M.; Lall, R.K.; Afolabi, S.O.; Singh, A.; Joshi, D.C.; Chiu, S.-Y.; Mukhtar, H.; Syed, D.N. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: Insights from in vitro and in vivo melanoma models. *Sci. Rep.* 2018, 8, 1–14. [CrossRef] [PubMed]

168. Liu-Smith, F.; Meyskens, F.L. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. *Mol. Nutr. Food Res.* 2016, 60, 1264–1274. [CrossRef] [PubMed]